CGT Industry Upgrade Series: Park Tour Shanghai Stop at Bayer Co.Lab Announces Guest Lineup

As Bayer’s global co-creation platform for the life sciences sector, Bayer Co.Lab is committed to providing startups with shared office spaces, advanced laboratory equipment, and personalized support services through its unique global network. Regarded as an ideal co-creation space for life science startups, Bayer Co.Lab enables resident companies to accelerate their innovation and business development by tapping into Bayer’s global R&D network and expertise, connecting with a worldwide innovation collaboration network, and leveraging Bayer’s extensive internal and external expert resources. Currently, Bayer Co.Lab has established a strategic presence in multiple global innovation hubs, including the United States, Germany, China, and Japan.

In China, Bayer has partnered with the Shanghai Biomedical Frontier Industry Innovation Center to jointly establish Bayer Co.Lab, located in Shanghai’s Zhangjiang landmark open innovation park, which features world-class laboratory facilities and office spaces.Bayer Co.Lab officially opened on September 26, 2024. It aims to empower 8 to 10 local startups focused on cell and gene therapy (CGT), oncology, and new technology platforms. Currently, Bayer Co.Lab is actively conducting recruitment and is poised to welcome its first cohort of tenant companies in China.

CoJourney is a professional gene and cell therapy CDMO integrating plasmid, viral vector, and mRNA production, preparation, and analytical testing. It has successful experience in filing Investigational New Drug (IND) applications for plasmids and viral vectors in both China and the United States, achieving zero deficiency letters. The company provides customized services including process development, cGMP manufacturing, analytical method development, and product release testing for plasmids, viral vectors, and mRNA.

Xingcheng Company was co-founded by senior CMC experts with commercialization experience in the gene and cell therapy fields, along with accomplished scientists and entrepreneurs. With dual headquarters located in Zhejiang, China, and Pennsylvania, USA, the company has established GMP manufacturing facilities for plasmids, viral vectors, and mRNA that comply with FDA, EU, and NMPA regulations. Equipped with advanced production equipment and analytical instruments, our team possesses extensive process development capabilities and practical expertise. Upholding the philosophy of “Action Rooted in Sincerity,” we leverage robust processes that exceed industry standards to ensure high-purity, high-yield, and cost-effective services for our partners, providing plasmid, viral vector, and mRNA preparation at various production scales from R&D to GMP grade.

Yeasen Biotechnology (Shanghai) Co., Ltd. is a high-tech enterprise focused on core raw materials in the upstream segment of the life science industry chain, engaged in the research and development, production, and sales of biological reagents across three major categories: molecular, protein, and cellular products. By integrating technological development pathways for molecular enzymes, proteins, antibodies, nucleic acids, and cells, Yeasen Biotechnology has become one of the few companies in China that simultaneously covers all three major categories of biological reagents, possessing both independent R&D capabilities for core technologies and large-scale production capacity.

The Company develops, manufactures, and sells thousands of types of biological reagents, meeting customers’ integrated procurement needs for various categories of biological reagents. Its core product portfolio spans multiple categories, including qPCR series, NGS series, reverse transcription series, nucleic acid extraction and purification series, PCR series, molecular cloning series, in vitro transcription series, antibodies, protein purification series, protein analysis series, recombinant proteins, cell analysis series, cell culture series, cell transfection series, and reporter gene detection series. These products are widely applied in fields such as life science research, diagnostic testing, and biopharmaceuticals.

Deepen Bio, founded in 2014, is a core upstream supplier in the field of cell and gene therapy (CGT), providing leading technical services and production tools for CGT companies, including viral vector production solutions and comprehensive solutions for cell therapy manufacturing.

In the section on viral vector production solutions, Shenyan Bio has designed and implemented its proprietary EuBioX automated laboratory system. By integrating advanced technologies such as big data analytics, bioinformatics, and automation, the company has innovatively developed EuLV, a platform for the large-scale production of lentiviral vectors based on stable producer cell lines.^®The system has resolved the technical bottlenecks in the large-scale production of lentiviral vectors, significantly enhancing production efficiency and product consistency while substantially reducing manufacturing costs through globally leading technology.

Meanwhile, as a leading domestic enterprise in automated cell preparation equipment, Shenyan Biotechnology has independently developed CellSep^®A series of cell processing systems, suitable for the standardized production of various cell-based therapies, along with the launch of equipment such as sterile tube welders, heat sealers, and wave bioreactors, providing an automated total solution for cell therapy manufacturing to comprehensively enhance production efficiency.

Shenyan Bio possesses unique interdisciplinary advantages and has accumulated profound technical expertise in the field of cell and gene therapy (CGT). Upholding its mission to “empower CGT and solve the industry’s most challenging problems,” the company will continue to expand the frontiers of therapeutic innovation.

Beijing Tongli Haiyuan Biotechnology Co., Ltd. specializes in the research, development, and manufacturing of GMP-grade raw materials and reagents for cell and gene therapy (CGT), providing comprehensive product and service solutions to CGT users. Its product portfolio includes magnetic beads for cell sorting, eukaryotic/prokaryotic recombinant proteins, serum-free culture media, and cell culture kits.

The company has been honored with titles such as National High-Tech Enterprise and Beijing Specialized, Refined, Differential, and Innovative SME. It has established a 3,200 m²²R&D laboratories and GMP-grade cleanroom facilities, including a magnetic bead-based cell sorting development platform, eukaryotic and prokaryotic protein expression engineering platforms, and a serum-free culture medium development platform. The facility is certified under both ISO 13485 and ISO 9001 quality management systems, and certain products have obtained U.S. FDA Drug Master File (DMF) registration.

Artery New Medicine is a media and research platform under VCBeat, focusing on the biopharmaceutical sector. It provides “in-depth” and “incremental” communication value to innovators and entrepreneurs through two dimensions: content and operations. In terms of content, it primarily features exclusive financing announcements, corporate interviews, the “Drug Developers” column, in-depth industry analyses, and track-specific reports. On the operational front, through its branded series “VB Think Tank,” it focuses on practical challenges, discusses industrial trends, and fosters tangible collaborations through the exchange of ideas.

Thematic Achievements:【CGT】【IPO Financial Report Analysis】【iPSC】【Nuclear Medicine Drugs】【Protein Degraders】【Upstream Tools】【Synthetic Biology】【Organoids and Organ-on-a-Chip】【VBThinkTank] etc.